Working…
ClinicalTrials.gov
ClinicalTrials.gov Menu

Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT03469362
Recruitment Status : Recruiting
First Posted : March 19, 2018
Last Update Posted : March 1, 2021
Sponsor:
Information provided by (Responsible Party):
Mark L. Gonzalgo, MD, University of Miami

Brief Summary:
Intracorporeal urinary diversion (ICD) provides superior postoperative outcomes compared to extracorporeal urinary diversion (ECD). The investigators' hypothesis that ICD may provide clinical benefit is based on principles of less bowel and ureteral handling, superior operating room workflow, less exposure to the external environment, and optimal visualization with ICD while utilizing a smaller incision compared to ECD. ICD should have less bowel-related complications, lower pain scores allowing patients to be discharged from the hospital sooner and regain functional independence more quickly.

Condition or disease Intervention/treatment Phase
Bladder Cancer Procedure: Extracorporeal Urinary Diversion Procedure: Intracorporal Urinary Diversion Device: Da Vinci Robot Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 88 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Other
Official Title: Randomized Clinical Trial of Intracorporeal vs Extracorporeal Urinary Diversion After Robot Assisted Radical Cystectomy
Actual Study Start Date : April 25, 2018
Estimated Primary Completion Date : June 2023
Estimated Study Completion Date : June 2026

Resource links provided by the National Library of Medicine


Arm Intervention/treatment
Experimental: Extracorporeal Urinary Diversion (ECD)
Participants will be randomized to receiving ECD after scheduled Robotic Assisted Radical Cystectomy (RARC).
Procedure: Extracorporeal Urinary Diversion
Extra-corporeal urinary diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit by hand.
Other Name: ECD

Experimental: Intracorporal Urinary Diversion (ICD)
Participants will be randomized to receiving ICD after scheduled Robotic Assisted Radical Cystectomy (RARC).
Procedure: Intracorporal Urinary Diversion
Intracorporal Urinary Diversion, provided as part of standard of care, will have the ureters sutured into the ileal conduit using the Da Vinci robot.
Other Name: ICD

Device: Da Vinci Robot
Da Vinci Robotic Surgical System




Primary Outcome Measures :
  1. 90-day Major Post-Operative Complication Rate [ Time Frame: 90 days ]
    Major complication rate at 90-days from RARC + urinary diversion using the modified Clavien-Dindo grading system. Major complication is defined as Clavien-Dindo Grade ≥ 3.


Secondary Outcome Measures :
  1. 90-day Any Post-Operative Complication Rate [ Time Frame: 90 days ]
    Any complication rates at 90-days from RARC + urinary diversion, using the modified Clavien-Dindo grading system as low grade (1-2) or high grade (3-5).

  2. Length of Hospital Stay in ECD vs ICD Study Participants [ Time Frame: About 2 weeks ]
    Length of hospital stay for study participants undergoing ECD versus ICD urinary diversion post-RARC, as recorded at hospital discharge.

  3. 90-day Readmission Rate [ Time Frame: 90 days ]
    Rate of readmission to hospital at 90 days post-RARC followed by ECD or ICD urinary diversion.

  4. Rate of Return to the Operating room within 90 days [ Time Frame: Up to 90 days ]
    Rate of return to the operating room within 90 days after RARC followed by ICD or ECD Urinary Diversion.

  5. Mortality Rate at 90 days [ Time Frame: 90 days ]
    Rate of mortality (death) at 90 days in study participants

  6. Rate of Bowel-Specific Complications [ Time Frame: Up to 36 months ]
    Rate of bowel-specific complications in study participants (including incidence of mechanical bowel obstruction, anastomotic leaks, and surgical site infections) and post operative pain. Bowel-specific complications will be assessed using the National Cancer Institute's Common Terminology Criteria for Adverse Events (CTCAE) version 4.

  7. Functional Independence Recovery as measured by the ADL Questionnaire [ Time Frame: Up to 36 months ]
    Rate of functional independence recovery as measured by patient-reported scores on the Activities of Daily Living (ADL) questionnaire. For the ADL, the total score ranges from 0 to 6, with the higher scores indicating functional improvement and lower scores indicating functional deterioration.

  8. Functional Independence Recovery as measured by the IADL Questionnaire [ Time Frame: Up to 36 months ]
    Rate of functional independence recovery as measured by an aggregate of patient-reported scores on the Instrumental Activities of Daily Living (IADL) questionnaire. For the IADL, the total score ranges from 0 to 8, with higher scores indicating functional functional improvement and lower scores indicating functional deterioration.

  9. Functional Independence Recovery as measured by the Hand Grip Strength Test. [ Time Frame: Up to 36 months ]
    The Hand Grip Strength Test measures the amount of static force that a participant's hand can squeeze around a dynamometer. The test is measured in kilograms.

  10. Functional Independence Recovery as measured by the Timed Up and Go (TUG) Walking Test [ Time Frame: Up to 36 months ]
    The TUG test times participants as they rise from a standard chair, walk 3 meters, turn, walk back and sit again. The test is measured in seconds.

  11. Health-Related Quality of Life (HRQoL) as assessed by SF-8 Health Survey [ Time Frame: Up to 36 months ]
    HRQoL measured by patient scores on the Short Form 8 (SF-8) Health Survey. The SF-8 is a questionnaire consisting of 8-items and two component summary scores: Physical component summary (PCS) and mental component summary (MCS). They are scored by weighting each score to a norm-based scoring model. The total scores will be reported as a percentile with higher score indicating better health-related quality of life.

  12. HRQoL as assessed by the FACT-VCI Questionnaire [ Time Frame: Up to 36 months ]
    HRQoL measured by patient scores on the Functional Assessment of Cancer Therapy-Vanderbilt Cystectomy Index (FACT-VCI) questionnaire. The FACT-VCI is a condition-specific instrument for patients undergoing radical cystectomy (RC) and urinary diversion (UD) for bladder cancer. The questionnaire consists of 44 items scored on a range from 0 ("Not at all") to 4 ("Very Much"), resulting in an ordinal Likert scale, with higher scores indicating a better HRQoL. The FACT-VCI measures quality of life across five domains: Physical wellbeing, social/family wellbeing, emotional wellbeing, functional wellbeing and an additional concerns subscale.



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 99 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Biopsy-proven urothelial cancer being considered for RARC.
  • Clinical stage T1-T4, N0-1, M0 or refractory carcinoma in situ.
  • Subject must be already scheduled to have a RARC at the discretion of the surgeon and with the patient's agreement.

Exclusion Criteria:

  • Inability to give informed consent
  • Prior major abdominal and pelvic open surgical procedures that would preclude a safe robotic approach, as determined by the treating surgeon.
  • At the discretion of the treating surgeon, any pre-existing condition such as severe chronic obstructive pulmonary disease that precludes a safe initiation or maintenance of pneumoperitoneum over a prolonged period of time and during surgery.
  • Age <18 or >99 years.

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT03469362


Contacts
Layout table for location contacts
Contact: Rody Barakat 305-243-2177 rxb773@med.miami.edu

Locations
Layout table for location information
United States, Florida
Rody Barakat Recruiting
Miami, Florida, United States, 33136
Contact: Rody L Barakat    305-243-2177    rxb773@med.miami.edu   
Principal Investigator: Mark L Gonzalgo, MD, PhD         
Sponsors and Collaborators
University of Miami
Investigators
Layout table for investigator information
Principal Investigator: Mark L Gonzalgo, MD, PhD University of Miami
Layout table for additonal information
Responsible Party: Mark L. Gonzalgo, MD, Professor of Clinical, University of Miami
ClinicalTrials.gov Identifier: NCT03469362    
Other Study ID Numbers: 20170004
First Posted: March 19, 2018    Key Record Dates
Last Update Posted: March 1, 2021
Last Verified: February 2021
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: Yes
Product Manufactured in and Exported from the U.S.: No
Additional relevant MeSH terms:
Layout table for MeSH terms
Urinary Bladder Neoplasms
Urologic Neoplasms
Urogenital Neoplasms
Neoplasms by Site
Neoplasms
Urinary Bladder Diseases
Urologic Diseases